Patient characteristics
| Characteristics . | R-CHOP . | R-COMP . | Total . | NA . | P value . |
|---|---|---|---|---|---|
| Age (y), median (range) | 71 (65-87) | 76 (65-88) | 73 (64-88) | — | < 001 |
| Age >80 y, n (%) | 8 (2) | 67 (22) | 75 (11) | — | < .001 |
| Male sex, n (%) | 177 (46) | 155 (50) | 332 (48) | — | .285 |
| IPI 3-5, n (%) | 188 (51) | 158 (55) | 346 (53) | 37 | .344 |
| Hb, median (range) | 12.5 (5.8-17.2) | 12.4 (7.1-17.5) | 12.5 (5.8-17.5) | 14 | .228 |
| Hb <12 g/dL, n (%) | 131 (34) | 129 (43) | 260 (38) | 14 | .021 |
| B symptoms, n (%) | 85 (22) | 92 (30) | 177 (26) | — | .023 |
| Bulky yes, n (%) | 122 (32) | 85 (28) | 207 (30) | 11 | .315 |
| sGA | — | < .001 | |||
| FIT | 338 (88) | 189 (61) | 527 (76) | ||
| UNFIT | 44 (11) | 100 (32) | 144 (21) | ||
| FRAIL | 1 (<1) | 19 (6) | 20 (6) | ||
| ADL | — | .003 | |||
| 6 | 353 (92) | 259 (84) | 612 (89) | ||
| 5 | 18 (5) | 34 (11) | 52 (7) | ||
| 0-4 | 12 (3) | 15 (5) | 27 (4) | ||
| IADL | — | < .001 | |||
| 8 | 332 (87) | 230 (75) | 562 (81) | ||
| 6-7 | 36 (9) | 57 (18) | 93 (13) | ||
| 0-5 | 15 (4) | 21 (7) | 36 (5) | ||
| Comorbidities, CIRS-G | |||||
| Heart > 1, n (%) | 32 (8) | 99 (32) | 131 (19) | — | < .001 |
| Liver > 1, n (%) | 11 (3) | 14 (5) | 25 (4) | — | .306 |
| Hypertension > 1, n (%) | 80 (21) | 117 (38) | 197 (29) | — | < .001 |
| Genitourinary > 1, n (%) | 28 (7) | 22 (7) | 50 (7) | — | 1.00 |
| Kidney > 1, n (%) | 5 (1) | 13 (4) | 18 (3) | — | .028 |
| Endocrine > 1, n (%) | 47 (12) | 65 (21) | 112 (17) | — | .020 |
| Musculoskeletal > 1, n (%) | 23 (6) | 28 (9) | 51 (7) | — | .143 |
| Nervous system> 1, n (%) | 9 (2) | 10 (3) | 19 (3) | — | .492 |
| Psychiatric>1, n (%) | 15 (4) | 17 (6) | 32 (5) | — | .364 |
| Risk factors for anthracycline use | < .001 | ||||
| None | 137 (36) | 38 (12) | 175 (25) | — | |
| At least one | 246 (64) | 270 (88) | 516 (75) | ||
| EPI score | 43 | < .001 | |||
| Low risk | 141 (39) | 76 (27) | 217 (33) | ||
| Intermediate risk | 196 (54) | 139 (49) | 335 (52) | ||
| High risk | 28 (8) | 68 (24) | 96 (15) |
| Characteristics . | R-CHOP . | R-COMP . | Total . | NA . | P value . |
|---|---|---|---|---|---|
| Age (y), median (range) | 71 (65-87) | 76 (65-88) | 73 (64-88) | — | < 001 |
| Age >80 y, n (%) | 8 (2) | 67 (22) | 75 (11) | — | < .001 |
| Male sex, n (%) | 177 (46) | 155 (50) | 332 (48) | — | .285 |
| IPI 3-5, n (%) | 188 (51) | 158 (55) | 346 (53) | 37 | .344 |
| Hb, median (range) | 12.5 (5.8-17.2) | 12.4 (7.1-17.5) | 12.5 (5.8-17.5) | 14 | .228 |
| Hb <12 g/dL, n (%) | 131 (34) | 129 (43) | 260 (38) | 14 | .021 |
| B symptoms, n (%) | 85 (22) | 92 (30) | 177 (26) | — | .023 |
| Bulky yes, n (%) | 122 (32) | 85 (28) | 207 (30) | 11 | .315 |
| sGA | — | < .001 | |||
| FIT | 338 (88) | 189 (61) | 527 (76) | ||
| UNFIT | 44 (11) | 100 (32) | 144 (21) | ||
| FRAIL | 1 (<1) | 19 (6) | 20 (6) | ||
| ADL | — | .003 | |||
| 6 | 353 (92) | 259 (84) | 612 (89) | ||
| 5 | 18 (5) | 34 (11) | 52 (7) | ||
| 0-4 | 12 (3) | 15 (5) | 27 (4) | ||
| IADL | — | < .001 | |||
| 8 | 332 (87) | 230 (75) | 562 (81) | ||
| 6-7 | 36 (9) | 57 (18) | 93 (13) | ||
| 0-5 | 15 (4) | 21 (7) | 36 (5) | ||
| Comorbidities, CIRS-G | |||||
| Heart > 1, n (%) | 32 (8) | 99 (32) | 131 (19) | — | < .001 |
| Liver > 1, n (%) | 11 (3) | 14 (5) | 25 (4) | — | .306 |
| Hypertension > 1, n (%) | 80 (21) | 117 (38) | 197 (29) | — | < .001 |
| Genitourinary > 1, n (%) | 28 (7) | 22 (7) | 50 (7) | — | 1.00 |
| Kidney > 1, n (%) | 5 (1) | 13 (4) | 18 (3) | — | .028 |
| Endocrine > 1, n (%) | 47 (12) | 65 (21) | 112 (17) | — | .020 |
| Musculoskeletal > 1, n (%) | 23 (6) | 28 (9) | 51 (7) | — | .143 |
| Nervous system> 1, n (%) | 9 (2) | 10 (3) | 19 (3) | — | .492 |
| Psychiatric>1, n (%) | 15 (4) | 17 (6) | 32 (5) | — | .364 |
| Risk factors for anthracycline use | < .001 | ||||
| None | 137 (36) | 38 (12) | 175 (25) | — | |
| At least one | 246 (64) | 270 (88) | 516 (75) | ||
| EPI score | 43 | < .001 | |||
| Low risk | 141 (39) | 76 (27) | 217 (33) | ||
| Intermediate risk | 196 (54) | 139 (49) | 335 (52) | ||
| High risk | 28 (8) | 68 (24) | 96 (15) |
Continuous covariate: Mann-Whitney test; categorical: Fisher exact test or χ2 test.
NA, not assessed.